Form 4 for TCRT Alaunos Therapeutics, Inc.
Accepted 2023-09-05 00:00:00 ET · period of report 2023-09-01 · accession 0000950170-23-046504 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2023-09-05 | 2023-09-01 | TCRT | Boyle Kevin S. Sr. | CEO, Dir | S - Sale | $0.14 | -68.0K | 798.2K | -8% | -$9,522 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-01 | S | D | 68,014 | $0.14 | 798,236 | D | — | — | (F1) Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |